Welcome to Weinberg on FDA, the official blog of The Weinberg Group Inc, a scientific and regulatory consulting firm based in Washington, D.C.! We plan to use this blog as a forum for discussion among our experienced staff of consultants and the pharmaceutical and biotechnology industries. Please post any comments or questions or email us at science@weinberggroup.com.
Search Our Site
About Weinberg on FDA
Welcome! As consultants at The Weinberg Group we are constantly analyzing and discussing breaking FDA news and decisions affecting the pharmaceutical and biotechnology industries. Every day we work to help our clients address regulatory requirements, improve manufacturing processes and support their products in the legal system, the media and in the court of public opinion. As a supplement to our work, this blog will provide the public with insights and opinions on FDA developments from our experienced staff of consultants.
Follow @weinberggroup on Twitter!
Tag Cloud
505(b)(2)
ANDA
bioequivalence
Biologics Price Competition and Innovation Act of 2009
Biosimiliars
blood product shortages
Cetero
Clinical Trial
draft guidance
Drug Development
Drug Expiration
drug labeling
drug safety
Drug Shortage
excipient
FDA
FDA patient safety
FDA regulatory process
GCP
GDUFA
GRAS
inactive ingredient guide
label changes
Levaquin
menthol
Nanomaterials
NDA
NDA Review
Obama
Office of Generic Drugs
Orphan Drugs
patents
patient safety
PDUFA
pharmacogenetics
Pimozide
Postmarket Safety
Product Risk
regulations
regulatory
The Animal Rule
Tobacco
TPSAC
User Fees
webinar
welcome
Archives
- July 2012 (2)
- June 2012 (3)
- May 2012 (4)
- April 2012 (6)
- March 2012 (4)
- February 2012 (4)
- January 2012 (5)
- December 2011 (6)
- October 2011 (1)
- August 2011 (2)
- July 2011 (1)
- May 2011 (1)


Recent Comments